Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: Serious concerns over the reliability of the PLATO trial

International Journal of Cardiology

Volumn 168, Issue 4, 2013, Pages 4076-4080

  Dinicolantonio, James J ^a,b   Tomek, Ales ^c  

^a Wegmans Pharmacy   (United States)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c NONE

Author keywords

Acute coronary syndrome; Clopidogrel; Myocardial infarction; Ticagrelor

Indexed keywords

CLOPIDOGREL; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DATA BASE; DRUG APPROVAL; DRUG INFORMATION; DRUG MONITORING; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; HUNGARY; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MEDICAL ERROR; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MORTALITY; OPEN STUDY; PATIENT MONITORING; POLAND; PRIORITY JOURNAL; PUBLICATION; RELIABILITY; RUSSIAN FEDERATION; SCIENTIFIC MISCONDUCT; TABLET FORMULATION; UNITED STATES; ANALOGS AND DERIVATIVES; BIOASSAY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; STANDARDS; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; ENDPOINT DETERMINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84886304355     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.020     Document Type: Article

References (18)

1. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
2. V.L. Serebruany Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified Thromb Haemost 105 5 May 2011 752 759
3. U.S. Food and Drug Administration Drug approval package: Brilinta (tricagrelor) tablets Medical Review 2013 [Available from http://www.accessdata. fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000MedR.pdf. Accessed 9 February 2013]
4. U.S. Food and Drug Administration Drug approval package: Brilinta (tricagrelor) tablets Statistical Review 2013 [Available from http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000StatR.pdf. Accessed 9 February 2013]
5. The FDA ticagrelor chemistry review(s) www.accessdata.fda.gov/drugsatfda- docs/nda/2011/022433Orig1s000ChemR.pdf
6. The FDA ticagrelor pharmacology review(s) www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/022433Orig1s000PharmR.pdf
7. The FDA ticagrelor secondary review www.fda.gov/downloads/AdvisoryCom- mittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAd- visoryCommittee/UCM220192.pdf
8. The FDA ticagrelor summary review www.accessdata.fda.gov/drugsatfda-docs/ nda/2011/022433Orig1s000SumR.pdf
9. Ticagrelor NDA letter of approval www.accessdata.fda.gov/drugsatfda-docs/ appletter/2011/022433Orig1s000ltr.pdf
10. V.L. Serebruany Ticagrelor FDA, approval issues revisited Cardiology 122 3 2012 144 147
11. V.L. Serebruany, J.J. DiNicolantonio, and M.M. Can Mortality in the TRACER and ATLAS ACS 2 trials: two more reasons to audit vital records in PLATO Cardiology 123 2012 11 14
12. J.J. DiNicolantonio, M.M. Can, and V.L. Serebruany Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: challenging PLATO mortality rates Int J Cardiol 164 3 Apr 15, 2013 255 258
13. J.J. DiNicolantonio, and V.L. Serebruany Exploring the reduction in myocardial infarction in the PLATO trial: which patients benefited on ticagrelor vs. clopidogrel? Int J Cardiol 165 3 May 25, 2013 396 397
14. J.J. DiNicolantonio, and V.L. Serebruany Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes Diabetes 62 3 2013 669 671
15. J.J. DiNicolantonio, and V.L. Serebruany Exploring the ticagrelor-statin interplay in the PLATO trial Cardiology 124 2 2013 105 107
16. J.J. DiNicolantonio, and V.L. Serebruany Comparing the safety of ticagrelor versus clopidogrel: insights from the FDA reports Ther Adv Cardiovasc Dis 7 1 2013 5 9
17. J.J. DiNicolantonio, and V.L. Serebruany Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: a net clinical harm? Stroke 43 12 2012 3409
18. J.J. Dinicolantonio, and G. Biondi-Zoccai Challenging ticagrelor's claimed reduction in the rate of definite stent thrombosis versus clopidogrel: insights from the FDA reports Int J Cardiol 168 2 2013 633 635